Biogen has received an NOC from Health Canada for Zurzuvae, a NAS, as a treatment for moderate or severe PPD in women.

The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.

This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.

The bipolar disorder (BD) market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and ...

Roche has received EC approval for its humanised monoclonal antibody Gazyva, in combination with mycophenolate mofetil (MMF).

As Datwyler unveils its next-generation flip cap made with bio-based polypropylene, we spoke with Camille Ermine about the challenges and opportunities of eco-design in parenteral packaging, from ...

Relapsed or refractory (R/R) follicular lymphoma (FL) remains a therapeutic challenge despite recent advances. Credit: evan_huang via Shutterstock. Bristol Myers Squibb’s golcadomide, a first-in-class ...